Vaccini, Reithera concludes Phase one: "We will produce 100 million in one year"

 "We aim to develop 100 million doses of the vaccine per year. The vaccine is stable at a temperature between 2 and 8 degrees." The president of the Italian vaccine developer Reithera, Antonella Folgore, said this at the presentation of the results of Phase 1 of the GRAd-CoV2 vaccine trial. "The vaccine induces antibodies and from preliminary data protects against infection and is well tolerated. These studies have delivered the clinical trial and will serve to consolidate the safety data." It is an important moment, today we talk about the results obtained in the study of phase 1. They are more than promising ". Thus Franco Locatelli, President of the Superior Health Council (ISS), during the press conference at Spallanzani regarding the outcomes and results of Phase 1 of the ReiThera vaccine trial." Let's try to achieve some independence also in the supply of vaccines ". Domenico Arcuri, extraordinary commissioner for the Covid-19 emergency underlined this at the press conference to present the results of phase 1 of the ReiThera GRAd-CoV2 vaccine trial." The Government has allocated sufficient resources to finance the subsequent development of the ReiThera experimentation - he explained -. The Government, through a public company, will enter ReiThera also with an equity operation, and the development contracts will be used to finance research and an incremental stabilization of production ". '' The Government, through a public company, will enter the capital of the company to support, also through an equity injection, the subsequent phase 2 and phase 3. '' Arcuri said. '' In exchange for this support we try to achieve two very important objectives. research, development and experimentation capacity that was not there a year ago and the second that of having the possibility of acquiring vaccine doses for our citizens in a stable and growing measure, even beyond the first urgency that in these hours afflicts us and that we are governing together with the European Union and centralized purchasing, '' he said. '' Whether we succeed or not will depend on the quality of the next phase of testing. one, we will certainly be able to leave behind a capacity for research, development and experimentation that was not there before. We think we have done a good thing that will become great, I am sure, when it comes to the conclusion, '' he concluded.           

Another 470,000 Pfizer vaccine doses are coming today.
In the field the Prefects on stocks and storage
Covid: ReiThera, recruitment of elderly volunteers proceeds
Coronavirus.
Locatelli: "179 thousand vaccinated, a not insignificant figure, fill the gap in regions"
Covid, Aifa authorizes Italian ReiThera vaccine test

Share

05 January 2021 "We aim to develop 100 million doses of the vaccine per year. The vaccine is stable at a temperature between 2 and 8 degrees". The president of the Italian vaccine developer Reithera, Antonella Folgore, said this at the presentation of the results of Phase 1 of the GRAd-CoV2 vaccine trial.

"The vaccine induces antibodies and from preliminary data protects against infection and is well tolerated. These studies have delivered the clinical trial and will serve to consolidate the safety data.

" It is an important moment, today we talk about the results obtained in the study of phase 1. They are more than promising ". Thus Franco Locatelli, President of the Superior Health Council (ISS), during the press conference at Spallanzani regarding the outcomes and results of Phase 1 of the ReiThera vaccine trial.

" Let's try to achieve some independence also in the supply of vaccines ". Domenico Arcuri, extraordinary commissioner for the Covid-19 emergency underlined this at the press conference to present the results of phase 1 of the ReiThera GRAd-CoV2 vaccine trial." The Government has allocated sufficient resources to finance the subsequent development of the ReiThera experimentation - he explained -. The Government, through a public company, will enter ReiThera also with an equity operation, and the development contracts will be used to finance research and an incremental stabilization of production ".

'' The Government, through a public company, will enter the capital of the company to support, also through an equity injection, the subsequent phase 2 and phase 3. '' Arcuri said. '' In exchange for this support we try to achieve two very important objectives. research, development and experimentation capacity that was not there a year ago and the second that of having the possibility of acquiring vaccine doses for our citizens in a stable and growing measure, even beyond the first urgency that in these hours afflicts us and that we are governing together with the European Union and centralized purchasing, '' he said. '' Whether we succeed or not will depend on the quality of the next phase of experimentation and, certainly we will be able to leave behind a capacity for research, development and experimentation that was not there before. We think we have done a good thing that will become great, I am sure, when it comes to the conclusion, '' he concluded.

Vaccini, Reithera concludes Phase one: "We will produce 100 million in one year"

You may like

Trends 24h

Latest